Marina Biotech (MRNA) 0.6000 $MRNA Marathon Pharma DMD

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Marina Biotech (MRNA) 0.6000 $MRNA

Marathon Pharma DMD drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Jan 19, 4:38PM CST

ROSG: 3.10 (-0.20), RNA: 18.65 (unch), PFE: 35.44 (+0.41), SRPT: 13.85 (-0.21), PTCT: 71.66 (-0.11)

PTC Therapeutics begins rolling NDA for DMD
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:20AM CST

ROSG: 3.10 (-0.20), RNA: 18.65 (unch), SRPT: 13.85 (-0.21), PFE: 35.44 (+0.41), PTCT: 71.66 (-0.11)

Marina Biotech and MiNA Therapeutics Announce License Agreement for the Development of saRNA-Based Therapeutics
Marketwired - Thu Dec 18, 7:01AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and MiNA Therapeutics Limited, the pioneer in RNA activation therapeutics, announced today that they have entered into a license agreement regarding the development and commercialization of small activating RNA (saRNA) based therapeutics utilizing MiNA's proprietary oligonucleotides and Marina's novel SMARTICLES nucleic acid delivery technology. MiNA will have full responsibility for the development and commercialization of any products arising under the Agreement and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $50 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration. Further terms of the Agreement were not disclosed.

Pfizer commences Phase 2 study in Duchenne Muscular Dystrophy
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 9:10AM CST

ROSG: 3.10 (-0.20), RNA: 18.65 (unch), SRPT: 13.85 (-0.21), PFE: 35.44 (+0.41), PTCT: 71.66 (-0.11)

Marina Biotech Reports That Licensee ProNAi Therapeutics Presented Interim Phase 2 Data on Its BCL2-Targeting DNAi(R) Therapeutic at ASH 2014
Marketwired - Tue Dec 09, 7:02AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its licensee, ProNAi Therapeutics, reported that a number of patients with relapsed or refractory Non-Hodgkin's Lymphoma treated with its first DNAi(R)-based therapeutic, PNT2258, achieved meaningful therapeutic outcomes and continue to exhibit durable clinical responses. PNT2258 is one of two nucleic acid-based therapeutics in clinical development which are formulated with Marina Biotech's proprietary SMARTICLES(R) delivery technology.

Market Maker Surveillance Report. BEBE, VSR, APT, LAKE, ECSL, MRNA, Winning Stocks With Lowest Price Friction For Tuesday, November 25th 2014
M2 - Wed Nov 26, 3:56AM CST
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4467 companies with "abnormal" market making, 2411 companies with positive Friction Factors and 2537 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. bebe stores inc (NASDAQ:BEBE), Versar Inc (NYSE:VSR), Alpha Pro Tech Ltd (NYSE:APT), Lakeland Industries Inc (NASDAQ:LAKE), ECARE SOLUTIONS INC (OTC:ECSL), MARINA BIOTECH INC (OTC:MRNA). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
BEBE: 3.47 (-0.02), APT: 2.23 (unch), LAKE: 9.62 (-0.02), VSR: 3.13 (unch)

Marina Biotech: A Forgotten And Grossly Undervalued Game Changer
The GeoTeam - Seeking Alpha - Tue Nov 25, 9:30AM CST
Earlier this month, investors witnessed another RNAi stock achieve incredible gains based on very early clinical trial data. The company, Regulus Therapeutics (NASDAQ: RGLS ), published its Hepatitis-C Phase I data from a pool of only 16 patients....
ROSG: 3.10 (-0.20), ISIS: 65.70 (+1.64), DRNA: 18.32 (+0.15), ALNY: 114.22 (+6.42), ARWR: 7.91 (-0.04), SRPT: 13.85 (-0.21), ALXN: 182.68 (+5.31), TKMR: 18.19 (+0.59), RGLS: 17.74 (+0.46)

Catabasis Pharmaceuticals' CAT-1004 tagged an Orphan Drug for DMD
Seeking Alpha - at Seeking Alpha - Mon Nov 24, 11:15AM CST

ROSG: 3.10 (-0.20), BMRN: 122.20 (+0.12), RNA: 18.65 (unch), SRPT: 13.85 (-0.21), PTCT: 71.66 (-0.11)

Marina Biotech Reports That Partner Mirna Therapeutics Presented Interim Phase 1 Data on Its First-in-Class microRNA-34 Mimic
Marketwired - Thu Nov 20, 7:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported that its partner, Mirna Therapeutics, presented interim safety and preliminary efficacy data from a multicenter, open-label Phase 1 clinical trial of MRX34. MRX34 is a microRNA34 mimic formulated in the Company's SMARTICLES(R) delivery technology. The data show that MRX34 has a manageable safety profile in patients with advanced primary liver cancer (hepatocellular carcinoma), other solid tumors with liver metastasis, and hematological malignancies. A maximum tolerated dose (MTD) was established at 110 mg/m2 for MRX34 administered twice weekly for three weeks followed by one week off. Dose escalation is on-going for a second dosing regimen wherein MRX34 is administered daily for five consecutive days followed by two weeks off. While this Phase 1 study is intended to investigate safety, tolerability, pharmacokinetics, and dosing regimens, treatment with MRX34 has provided early signals of clinical activity in advanced cancer patients with primary liver, neuroendocrine, colorectal and small cell lung cancers, as well as diffuse large B-cell lymphoma.

Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance
Marketwired - Wed Nov 19, 3:10PM CST
Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD).
ROSG: 3.10 (-0.20)

Marina Biotech Announces Third Quarter 2014 Financial Results
Marketwired - Mon Nov 17, 6:30AM CST
Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today reported financial results for the three months ended September 30, 2014.

Prosensa begins FDA submission process for DMD drug candidate
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 2:37PM CDT

ROSG: 3.10 (-0.20), RNA: 18.65 (unch), SRPT: 13.85 (-0.21), PTCT: 71.66 (-0.11)

Marina Biotech Announces the Election of Donald A. Williams to Its Board of Directors
Marketwire - Tue Sep 16, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that all five of the director nominees submitted to the company's stockholders for election at Marina Biotech's 2014 Annual Meeting of Stockholders held on September 15, 2014 in San Diego, CA were elected to serve as members of the company's board of directors. The director nominees included four incumbent directors -- J. Michael French, Stefan Loren, Ph.D., Joseph W. Ramelli and Philip C. Ranker -- as well as new board member Donald A. Williams. In addition to the election of all of the director nominees, the recommendations of the Board with respect to all five of the other items that were described in the proxy statement for consideration at the Annual Meeting also received sufficient stockholder support.

Marina Biotech Announces the Continued Worldwide Expansion of Its Delivery Technology Intellectual Property Estate
Marketwire - Thu Sep 11, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that it had received patent protection for its comprehensive and diverse nucleic acid delivery platform with patent grants covering the following delivery technologies: SMARTICLES(R) in Europe; TransKingdom RNA(TM) interference (tkRNAi) in Japan; Di-terminal Amino Acid Lipids (DILA2) in Australia; and lipopeptide nucleic acid delivery in China. These grants support a global intellectual property estate broadly covering the Company's biochemistry and delivery technologies with over 100 issued or allowed patents and over 90 pending U.S. and foreign patent applications.

Marina Biotech to Present Rare Disease Clinical Strategy at Upcoming Investor Conferences
Marketwire - Wed Sep 03, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that J. Michael French, President and CEO, will present at the Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10, 2014 at the Palace Hotel in New York and at the Aegis Capital Corporation 2014 Healthcare and Technology Conference on Friday, September 12, 2014 at the Wynn Encore in Las Vegas.

Marina Biotech Regains Compliance With Exchange Act Reporting Obligations
Marketwire - Wed Aug 20, 6:31AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company has become current with respect to its obligation to file reports with the Securities and Exchange Commission under Section 13 of the Securities Exchange Act of 1934, having filed its Annual Reports on Form 10-K for the fiscal years ended December 31, 2012 and December 31, 2013, its Quarterly Reports on Form 10-Q for the first three quarters of the 2013 fiscal year, and its Quarterly Reports on Form 10-Q for the first and second fiscal quarters of 2014 over the past thirty days. In addition, the Company is using its proprietary nucleic acid drug discovery platform to refocus research and developments efforts on expanding its clinical pipeline with the addition of two orphan disease programs.

Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial
Marketwire - Thu Jun 12, 6:30AM CDT
Marina Biotech, Inc. (PINKSHEETS: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, today announced that the Company's licensee, Mirna Therapeutics, has reported that Mirna enrolled the first patient in the hematological malignancy cohort of its ongoing Phase 1 clinical trial of MRX34. MRX34 is Mirna's lead product candidate and first microRNA mimic in human clinical trials in the oncology space. Under terms of the license agreement, Mirna has full responsibility for the development and commercialization of any products which arise during the license period, and Marina Biotech could receive up to $60 million in total upfront, clinical and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fresha Pushes Beauty Bookings Into AI Search Channels

Updated Category News Views 17

A haircut search is turning into a distribution fight, and Fresha has planted itself squarely in the middle of it. The company’s new Partner Network pushes its beauty and wellness marketplace beyond its own app and website into Google Search, Google Maps, Google’s AI experiences, ChatGPT, Claude, and eventually Alexa. That sounds like another glossy AI announcement...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 85

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Live Nation Tests Creator Content With Morgan Jay Series

Updated Category News Views 57

A comedian turning crowd work into songs is hardly a boardroom event, but this one has a useful wrinkle: Live Nation Studios put financing behind it. Morgan Jay and Austin-based agency Hello Party launched Music Therapy with Morgan Jay on YouTube on November 18, with Kam Patterson opening the season. The show pairs Jay and celebrity guests for loose conversation,...

Continue Reading
ROBOTERA Puts Humanoid Robots Into Logistics Night Work

Updated Category News Views 76

Midnight warehouse work is where a humanoid robot has to quit posing and earn its keep. ROBOTERA arrived at the 2026 APEC CEO Summit with a useful answer to the usual shiny-robot nonsense: it says its machines are already working in logistics centers, handling parcel induction and taking on repetitive, physically demanding shifts that people understandably do not line up...

Continue Reading
WeWalk Brings Diabetes Support Back to Dubai Science Park

Updated Category News Views 104

Before sunrise on 21 November, a 3.5 km route in Dubai Science Park will carry a purpose bigger than sneakers and weekend fitness. WeWalk is returning for its seventh edition, with TECOM Group PJSC and Dubai Charity Association again putting the event behind support for children living with diabetes. That deserves to be said plainly: this is a community health effort, not...

Continue Reading
SKINformed Bets on Skin Longevity Over Quick Fixes

Updated Category News Views 41

Wrinkle panic has been a very profitable racket for a long time, and SKINformed is trying to sidestep it. The physician-founded skincare brand is planting its flag on “SKINgevity,” a term it uses to describe long-term skin health rather than a frantic hunt for an overnight rewind. That is a sensible read on where beauty consumers appear to be headed: less appetite for...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 16

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
NKT’s Q3 Margin Holds Up as Capacity Spending Bites

Updated Category News Views 70

Steel, copper and giant cable drums do not make for a pretty quarterly story, but NKT’s numbers have a sturdier backbone than the headline revenue dip suggests. The company delivered EUR 111 million of operational EBITDA in Q3 2026, down from EUR 119 million a year earlier, while its margin at standard metal prices edged up to 16.6% from 16.4%. That is not fireworks. It...

Continue Reading
Makers Nutrition Backs Families Through Friends of Karen

Updated Category News Views 9

A thousand dollars in gift cards can look modest beside the noise of holiday marketing, but it lands differently when a family is carrying the weight of a child’s life-threatening illness. Makers Nutrition, a Hauppauge, New York-based private-label and custom supplement manufacturer, has donated $1,000 in gift cards to Friends of Karen for the nonprofit’s annual...

Continue Reading
Kuaishou’s AI Push Meets a Brutal Earnings Reality

Updated Category News Views 111

Kuaishou just put a very expensive wrinkle in its AI story. The third-quarter figures are not a minor wobble: revenue dropped 11.1% year over year to RMB31.6 billion, gross margin slid from 54.7% to 48.2%, and the company swung from a RMB4.5 billion profit to a RMB959 million loss. For holders of 01024, that is the sort of earnings release that demands less daydreaming...

Continue Reading

Top 5 Most Recently Viewed Articles

BMO Continues to Support United Natural Foods with Price Target

Updated Category News Views 79

BMO Capital Markets Maintains Support for United Natural Foods BMO Capital Markets has reaffirmed its position regarding United Natural Foods (NYSE: UNFI), assigning a Market Perform rating with a price target set at $23.00. This decision came after productive discussions held with UNFI's senior executives, including CEO Sandy Douglas and CFO Matteo Tarditi, focusing on...

Continue Reading
HONOR's Ambitious Shift to AI Device Ecosystem Strategy

Updated Category News Views 202

HONOR's Bold New Strategy for AI Device Ecosystem In an ambitious move, global technology brand HONOR has laid out a comprehensive strategy to transform from a traditional smartphone manufacturer into a leader in the AI device ecosystem. This announcement marks a significant pivot towards embracing advanced technologies designed to maximize human potential. The new...

Continue Reading
Roche's Strategic Move: Acquiring 89bio for Innovative Therapies

Updated Category News Views 254

Roche's Strategic Acquisition of 89bio Roche's recent decision to acquire 89bio, a clinical-stage biopharmaceutical company, highlights its commitment to enhancing treatment options for patients suffering from metabolic diseases. This acquisition centers around 89bio’s innovative therapy, pegozafermin, which is showing promise for treating moderate to severe Metabolic...

Continue Reading
Baby Safety Alliance Elevates Parent Confidence in Products

Updated Category News Views 137

Baby Safety Alliance Strengthens Trust for Parents The Baby Safety Alliance is excited to announce a significant expansion of its Verification Program. This vital initiative, previously recognized as the JPMA Certification Program, aims to simplify the process for parents seeking safe and reliable products for their babies and children. Growth of the Verification Program...

Continue Reading
Ken Kendrick: A Journey of Resilience and Recognition

Updated Category News Views 646

Ken Kendrick’s Recognition by the Horatio Alger Association Ken Kendrick, the managing general partner of the Arizona Diamondbacks, has recently been honored by the Horatio Alger Association, which has selected him for its Member Class of 2025. This prestigious recognition is awarded to individuals who have overcome personal and professional adversities, showcasing...

Continue Reading